Humanized complement 5A receptor 1 antibodies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-12227587-B2
Application number	US-202418415419-A
Country	US
Kind code	B2
Filing date	Jan 17, 2024
Priority date	Jan 13, 2021
Publication date	Feb 18, 2025
Grant date	Feb 18, 2025

Abstract

The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

First claim

The invention claimed is:

1. A method of making an antibody or antigen binding fragment thereof that binds complement component 5a receptor 1 (C5aR1),
wherein the method comprises culturing a host cell comprising a nucleic acid encoding the C5aR1 antibody or antigen binding fragment thereof, and culturing the cell under conditions that allow production of the antibody or antigen binding fragment thereof,
wherein the C5aR1 antibody or antigen binding fragment thereof comprises a VH region, wherein the VH comprises three heavy chain complementarity determining regions (HCDRs), wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, respectively, and
a VL region, wherein the VL comprises three light chain complementarity determining regions (LCDRs), wherein the LCDR1, LCDR2, and LCDR3 sequences comprise the amino acid sequences of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, respectively.

2. The method of claim 1 , wherein the VH comprises an amino acid sequence at least 95% identical to SEQ ID NO: 14.

3. The method of claim 2 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14.

4. The method of claim 1 , wherein the VL comprises an amino acid sequence at least 95% identical to SEQ ID NO: 25.

5. The method of claim 4 , wherein the VL comprises the amino acid sequence of SEQ ID NO: 25.

6. The method of claim 1 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 14; and wherein the VL comprises the amino acid sequence of SEQ ID NO: 25.

7. The method of claim 1 , wherein the antibody or antigen binding fragment thereof, further comprises a Fc region.

8. The method of claim 7 , wherein the Fc domain is independently selected from IgG1, IgG2, IgG3, and IgG4.

9. The method of claim 1 , wherein the antibody or antigen binding fragment is humanized.

10. The method of claim 1 , wherein the VH or the VL has been modified to enhance the stability of the molecule.

Assignees

• Visterra Inc

Inventors

• Viswanathan Karthik
• Booth Brian
• Ramakrishnan Boopathy
• Wollacott Andrew
• Babcock Gregory
• Shriver Zachary
• Olinski Lauren

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/94

  Stability, e.g. half-life, pH, temperature or enzyme-resistance · CPC title

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title